IDYA
Income statement / Annual
Last year (2024), IDEAYA Biosciences, Inc.'s total revenue was $7.00 M,
a decrease of 70.07% from the previous year.
In 2024, IDEAYA Biosciences, Inc.'s net income was -$274.48 M.
See IDEAYA Biosciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$7.00 M |
$23.39 M |
$50.93 M |
$27.94 M |
$19.54 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$4.01 M
|
$2.10 M
|
$1.73 M
|
$39.70 M
|
$1.25 M
|
$886,000.00
|
$391,000.00
|
| Gross Profit |
$7.00 M
|
$19.38 M
|
$48.83 M
|
$26.22 M
|
-$20.16 M
|
-$1.25 M
|
-$886,000.00
|
-$391,000.00
|
| Gross Profit Ratio |
1
|
0.83
|
0.96
|
0.94
|
-1.03
|
0
|
0
|
0
|
| Research and Development Expenses |
$294.67 M
|
$129.51 M
|
$89.54 M
|
$58.16 M
|
$39.70 M
|
$34.32 M
|
$31.75 M
|
$12.38 M
|
| General & Administrative Expenses |
$39.30 M
|
$28.31 M
|
$23.90 M
|
$20.05 M
|
$15.18 M
|
$9.95 M
|
$4.67 M
|
$2.05 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$39.30 M
|
$28.31 M
|
$23.90 M
|
$20.05 M
|
$15.18 M
|
$9.95 M
|
$4.67 M
|
$2.05 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$8,000.00
|
$77,000.00
|
$2.43 M
|
| Operating Expenses |
$333.98 M
|
$157.81 M
|
$113.43 M
|
$78.21 M
|
$54.88 M
|
$44.27 M
|
$36.42 M
|
$14.44 M
|
| Cost And Expenses |
$333.98 M
|
$157.81 M
|
$113.43 M
|
$78.21 M
|
$54.88 M
|
$44.27 M
|
$36.42 M
|
$14.44 M
|
| Interest Income |
$52.50 M
|
$21.47 M
|
$3.85 M
|
$506,000.00
|
$849,000.00
|
$2.29 M
|
$1.99 M
|
$150,000.00
|
| Interest Expense |
$0.00
|
$0.00
|
$3.85 M
|
$0.00
|
$849,000.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$4.01 M
|
$2.10 M
|
$1.73 M
|
$1.38 M
|
$1.25 M
|
$886,000.00
|
$391,000.00
|
| EBITDA |
-$326.98 M |
-$130.42 M |
-$60.40 M |
-$48.54 M |
-$33.96 M |
-$43.03 M |
-$35.53 M |
-$14.05 M |
| EBITDA Ratio |
-46.71
|
-5.58
|
-1.23
|
-1.8
|
-1.81
|
0
|
0
|
0
|
| Operating Income Ratio |
-46.71
|
-5.75
|
-1.23
|
-1.8
|
-1.81
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$52.50 M
|
$21.47 M
|
$3.85 M
|
$506,000.00
|
$849,000.00
|
$2.30 M
|
$2.07 M
|
$2.58 M
|
| Income Before Tax |
-$274.48 M
|
-$112.96 M
|
-$58.66 M
|
-$49.76 M
|
-$34.50 M
|
-$41.98 M
|
-$34.35 M
|
-$11.86 M
|
| Income Before Tax Ratio |
-39.21
|
-4.83
|
-1.15
|
-1.78
|
-1.77
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$3.85 M
|
-$2.23 M
|
-$2.23 M
|
-$3.53 M
|
$2.07 M
|
-$150,000.00
|
| Net Income |
-$274.48 M
|
-$112.96 M
|
-$54.81 M
|
-$47.53 M
|
-$32.27 M
|
-$38.44 M
|
-$34.35 M
|
-$11.86 M
|
| Net Income Ratio |
-39.21
|
-4.83
|
-1.08
|
-1.7
|
-1.65
|
0
|
0
|
0
|
| EPS |
-3.36 |
-1.96 |
-1.32 |
-1.35 |
-1.31 |
-1.9 |
-2.41 |
-0.83 |
| EPS Diluted |
-3.36 |
-1.96 |
-1.32 |
-1.35 |
-1.31 |
-1.9 |
-2.41 |
-0.83 |
| Weighted Average Shares Out |
$81.68 M
|
$57.52 M
|
$41.44 M
|
$35.25 M
|
$24.72 M
|
$20.23 M
|
$14.24 M
|
$14.24 M
|
| Weighted Average Shares Out Diluted |
$81.68 M
|
$57.52 M
|
$41.44 M
|
$35.25 M
|
$24.72 M
|
$20.23 M
|
$14.24 M
|
$14.24 M
|
| Link |
|
|
|
|
|
|
|
|
